RU2197970C2 - Композиции и способы, предназначенные для снижения глазной гипертензии - Google Patents

Композиции и способы, предназначенные для снижения глазной гипертензии Download PDF

Info

Publication number
RU2197970C2
RU2197970C2 RU99121641/14A RU99121641A RU2197970C2 RU 2197970 C2 RU2197970 C2 RU 2197970C2 RU 99121641/14 A RU99121641/14 A RU 99121641/14A RU 99121641 A RU99121641 A RU 99121641A RU 2197970 C2 RU2197970 C2 RU 2197970C2
Authority
RU
Russia
Prior art keywords
composition
preservative
composition according
group
prostaglandins
Prior art date
Application number
RU99121641/14A
Other languages
English (en)
Russian (ru)
Other versions
RU99121641A (ru
Inventor
Кеннет Уоррен РИД
Шаофэн ЮНЬ
Мэри СОУ
Реджайна Флинн ПИКОК
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2197970(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU99121641A publication Critical patent/RU99121641A/ru
Application granted granted Critical
Publication of RU2197970C2 publication Critical patent/RU2197970C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
RU99121641/14A 1997-03-17 1998-03-13 Композиции и способы, предназначенные для снижения глазной гипертензии RU2197970C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
US08/819,221 1997-03-17

Publications (2)

Publication Number Publication Date
RU99121641A RU99121641A (ru) 2001-08-20
RU2197970C2 true RU2197970C2 (ru) 2003-02-10

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99121641/14A RU2197970C2 (ru) 1997-03-17 1998-03-13 Композиции и способы, предназначенные для снижения глазной гипертензии

Country Status (32)

Country Link
EP (1) EP0969846B2 (cg-RX-API-DMAC10.html)
JP (2) JP4920124B2 (cg-RX-API-DMAC10.html)
KR (1) KR100555818B1 (cg-RX-API-DMAC10.html)
CN (1) CN1236775C (cg-RX-API-DMAC10.html)
AR (2) AR002194A1 (cg-RX-API-DMAC10.html)
AT (1) ATE257385T1 (cg-RX-API-DMAC10.html)
AU (1) AU738781B2 (cg-RX-API-DMAC10.html)
BR (2) BRPI9816218B1 (cg-RX-API-DMAC10.html)
CA (1) CA2280089C (cg-RX-API-DMAC10.html)
CL (1) CL2009001870A1 (cg-RX-API-DMAC10.html)
CO (1) CO4940427A1 (cg-RX-API-DMAC10.html)
CY (1) CY2526B1 (cg-RX-API-DMAC10.html)
CZ (1) CZ299833B6 (cg-RX-API-DMAC10.html)
DE (1) DE69820997T3 (cg-RX-API-DMAC10.html)
DK (1) DK0969846T4 (cg-RX-API-DMAC10.html)
EE (1) EE04091B1 (cg-RX-API-DMAC10.html)
ES (1) ES2214706T5 (cg-RX-API-DMAC10.html)
HU (1) HU228896B1 (cg-RX-API-DMAC10.html)
ID (1) ID22389A (cg-RX-API-DMAC10.html)
IL (1) IL131041A0 (cg-RX-API-DMAC10.html)
MY (1) MY122237A (cg-RX-API-DMAC10.html)
NO (1) NO327713B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ337322A (cg-RX-API-DMAC10.html)
PE (1) PE61899A1 (cg-RX-API-DMAC10.html)
PL (1) PL197509B1 (cg-RX-API-DMAC10.html)
PT (1) PT969846E (cg-RX-API-DMAC10.html)
RU (1) RU2197970C2 (cg-RX-API-DMAC10.html)
SI (1) SI0969846T2 (cg-RX-API-DMAC10.html)
TW (1) TW527187B (cg-RX-API-DMAC10.html)
UA (1) UA63938C2 (cg-RX-API-DMAC10.html)
WO (1) WO1998041208A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA982188B (cg-RX-API-DMAC10.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
RU2397776C2 (ru) * 2005-03-31 2010-08-27 Др. Герхард Манн Хем.-Фарм. Фабрик Гмбх Офтальмологический состав
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
RU2462234C2 (ru) * 2006-03-17 2012-09-27 Джонсон Энд Джонсон Вижн Кэа, Инк. Способы стабилизации окислительно нестабильных композиций
RU2465898C2 (ru) * 2006-10-31 2012-11-10 Алькон Рисерч, Лтд. Модуляторы связывания pai-1 для лечения глазных болезней
EA019867B1 (ru) * 2007-10-08 2014-06-30 Фовея Фармасьютикалс Водные офтальмологические препараты
RU2776374C2 (ru) * 2017-12-28 2022-07-19 Сантен Фармасьютикал Ко., Лтд. Фармацевтический препарат, содержащий пиридиламиноуксусную кислоту

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
CN1933833B (zh) * 2004-03-18 2011-09-07 株式会社·R-技术上野 含有噻唑衍生物的含水组合物
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007105691A1 (ja) * 2006-03-13 2007-09-20 R-Tech Ueno, Ltd. 水性組成物
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PL2787968T3 (pl) 2011-12-07 2020-08-24 Allergan, Inc. Wydajne dostarczanie lipidów do ludzkiego filmu łzowego z użyciem wrażliwego na sól układu emulsyjnego
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
KR102487299B1 (ko) 2014-11-25 2023-01-10 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
US11752175B2 (en) * 2018-09-21 2023-09-12 Cornell University Compositions and methods for glaucoma
CA3136356A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042936C (en) * 1990-05-22 2002-04-30 Ryuji Ueno Treatment of ocular hypertension with a synergistic combination for ophthalmic use
WO1992013836A1 (en) * 1991-02-07 1992-08-20 Allergan, Inc. 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
МАШКОВСКИЙ М.Д. Лекарственные средства. - М.: Медицина, 1986, ч.1, с. 218-221, ч.2, с. 523-525. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
RU2397776C2 (ru) * 2005-03-31 2010-08-27 Др. Герхард Манн Хем.-Фарм. Фабрик Гмбх Офтальмологический состав
RU2462234C2 (ru) * 2006-03-17 2012-09-27 Джонсон Энд Джонсон Вижн Кэа, Инк. Способы стабилизации окислительно нестабильных композиций
RU2465898C2 (ru) * 2006-10-31 2012-11-10 Алькон Рисерч, Лтд. Модуляторы связывания pai-1 для лечения глазных болезней
EA019867B1 (ru) * 2007-10-08 2014-06-30 Фовея Фармасьютикалс Водные офтальмологические препараты
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
RU2776374C2 (ru) * 2017-12-28 2022-07-19 Сантен Фармасьютикал Ко., Лтд. Фармацевтический препарат, содержащий пиридиламиноуксусную кислоту

Also Published As

Publication number Publication date
NO327713B1 (no) 2009-09-14
AU7035398A (en) 1998-10-12
PL197509B1 (pl) 2008-04-30
HU228896B1 (en) 2013-06-28
NO994481D0 (no) 1999-09-16
AR011192A1 (es) 2000-08-02
DK0969846T4 (da) 2010-12-20
ES2214706T5 (es) 2011-02-02
IL131041A0 (en) 2001-01-28
JP4920124B2 (ja) 2012-04-18
PT969846E (pt) 2004-05-31
DK0969846T3 (da) 2004-04-13
BRPI9816218B1 (pt) 2016-04-12
DE69820997T2 (de) 2004-12-09
EP0969846A1 (en) 2000-01-12
PE61899A1 (es) 1999-06-30
CN1236775C (zh) 2006-01-18
HUP0002194A2 (hu) 2000-12-28
JP2010043110A (ja) 2010-02-25
EP0969846B1 (en) 2004-01-07
ZA982188B (en) 1998-09-17
WO1998041208A1 (en) 1998-09-24
CZ325799A3 (cs) 2000-01-12
AU738781B2 (en) 2001-09-27
EE04091B1 (et) 2003-08-15
EE9900410A (et) 2000-04-17
CZ299833B6 (cs) 2008-12-10
ATE257385T1 (de) 2004-01-15
CA2280089C (en) 2009-03-03
CL2009001870A1 (es) 2010-01-22
CO4940427A1 (es) 2000-07-24
ES2214706T3 (es) 2004-09-16
DE69820997D1 (de) 2004-02-12
SI0969846T2 (sl) 2010-12-31
CA2280089A1 (en) 1998-09-24
MY122237A (en) 2006-04-29
SI0969846T1 (en) 2004-06-30
NO994481L (no) 1999-09-16
NZ337322A (en) 2001-05-25
JP2001515502A (ja) 2001-09-18
KR100555818B1 (ko) 2006-03-03
ID22389A (id) 1999-10-07
CN1249687A (zh) 2000-04-05
BR9808016A (pt) 2000-03-08
CY2526B1 (en) 2006-02-08
KR20000076330A (ko) 2000-12-26
EP0969846B2 (en) 2010-08-25
UA63938C2 (uk) 2004-02-16
TW527187B (en) 2003-04-11
HUP0002194A3 (en) 2012-08-28
HK1026841A1 (en) 2000-12-29
AR002194A1 (es) 1998-01-07
DE69820997T3 (de) 2011-10-06
PL335168A1 (en) 2000-04-10

Similar Documents

Publication Publication Date Title
AU738781B2 (en) Compositions and methods for reducing ocular hypertension
US6770675B2 (en) Compositions and methods for reducing ocular hypertension
RU2460516C2 (ru) Офтальмические эмульсии масло-в-воде, содержащие простагландины
EP0258865B1 (en) Aqueous opthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US4883819A (en) Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
CA2502437C (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
EP0242580B1 (en) Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma
EP0473159A1 (en) Stable aqueous preparation
JP2811036B2 (ja) ビタミンe点眼剤
EP0824916B1 (en) Pranoprofen eyedrops containing organic amine
EP0562188B1 (en) Composition for tissues to sustain viability and biological functions in surgery and storage
US4459309A (en) Compositions and methods of lowering intraocular pressure in the hypertensive mammalian eye
HK1026841B (en) Compositions and methods for reducing ocular hypertension
CA2076023A1 (en) Use of 5-trans prostaglandin f as an ocular hypotensive agent
WO2003020283A2 (en) Method for treating diabetic retinopathy
JPS62263109A (ja) リン脂質を安定に配合する方法
HK1070830B (en) Hypotensive lipid and timolol compositions and methods of using same

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150314